Elinzanetant

Elinzanetant has been studied in 40 papers since 2024: 6 trials in people, 33 reviews; 31 in the past year. It is an approved medicine. The newest story, Oct 25, 2026: “Elinzanetant’s safety profile appeared favorable in women”.

InterventionApproved 2025

40 papers study it2 more mention it52 findingsUpdated

PubChem

9 new papers in 30 daysSee all 42 papers on elinzanetant

At a glance

Reviews describe reduced menopausal vasomotor symptoms and increased treatment-emergent adverse events with elinzanetant, both reproduced by independent labs. A trial reports less bone-density loss in postmenopausal women; another reports reduced wakefulness after sleep onset at four weeks but no clear effect at twelve weeks. Bayer sponsors its aging trials and employs some authors.

52 findings in 29 papers from 2024 to 2026, 17 of them since April 2026

Independent labs found the same change in people. 11 independent labs in 9 countries; 17 trials, 7 about aging, 10 with no results posted.

“In the clinical program (phases 1‒3), there was no imbalance between the elinzanetant and placebo groups in alanine aminotransferase (ALT) elevations up to 5×, 10×, or 20× the upper limit of normal (ULN).”
Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist ElinzanetantDrug safety2026doi:10.1007/s40264-026-01663-9

1 of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 11 independent labs in 9 countries
  • 1 finding against
  • 17 trials, 7 about aging, 10 with no results posted
  • Funders: Bayer and 3 more
  • 16 of 23 findings with company ties
  • 17 of 17 trials sponsored by its developers
  • Human trial6
  • In silico1

Studies in people

3 studies gave elinzanetant to people and measured what changed.

What changedDesignPeopleSource

down: Decreases wakefulness after sleep onsetLS-mean difference = -22.50 minutes, 90% CI: -35.47, -9.52

no change: Has no effect on wakefulness after sleep onsetLS-mean difference = -0.94 minutes, 90% CI: -13.96, 12.09

up: Improves sleep continuity

Randomized trial4 weeks110 peopleWomen40-65 yearsPostmenopausal women; moderate-to-severe VMS and sleep disturbanceSleep, Jul 28, 2026

no change: Has no effect on alanine aminotransferase0.5% vs 0.4%

no change: Has no effect on drug-induced liver injury

Review of trials52 weeks1,697 people pooledWomenPostmenopausal womenDrug safety, Mar 18, 2026

down: Decreases bone mineral density lossfemoral neck 0.00% vs -1.22%, total hip -0.70% vs -1.37%, lumbar spine -0.57% vs -1.22%

down: Decreases osteocalcin

up: Increases lean mass index

Randomized trial52 weeksWomenPostmenopausal women; postmenopausal womenENDO 2025 abstract, Oct 22, 2025

What did studies of elinzanetant find?

28

Studies of elinzanetant measured 28 outcomes, among them vasomotor symptoms, vasomotor symptoms and sleep disturbance.

Vasomotor symptoms

downin humans6downin reviews1

7 studies
  1. Elinzanetant decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -0.51, 95% CI -0.95 to -0.07).

    “elinzanetant (SMD -0.51, 95% CI -0.95 to -0.07)”

    Reviewbreast cancer-related vasomotor symptoms; compared with placebofemales

    Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis

    Frontiers in pharmacology

  2. Elinzanetant decreases vasomotor symptoms in humans (moderate to severe menopausal vasomotor symptoms).

    “elinzanetant significantly reduced the frequency and severity of menopausal VMS (primary endpoints), with reductions in frequency evident as early as week 1”

    Reviewmoderate to severe menopausal vasomotor symptomsoralup to 52 weeksfemales

    Elinzanetant in moderate to severe menopausal vasomotor symptoms: a profile of its use

    Drugs & Therapy Perspectives

  3. Elinzanetant decreases vasomotor symptoms during and after menopause.

    “A neurokinin inhibitor that can alleviate vasomotor symptoms during and after menopause.”

    Reviewduring and after menopause

    Elinzanetant

    pharma-kritik

  4. Elinzanetant decreases vasomotor symptoms in humans (associated with natural/surgical menopause or endocrine therapy for breast cancer).

    “By week 12, all studies showed significant reductions vs. placebo, with benefits maintained for up to 50 weeks.”

    Reviewassociated with natural/surgical menopause or endocrine therapy for breast cancerup to 50 weeksfemales

    Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program

    Maturitas

  5. Elinzanetant decreases vasomotor symptoms in menopause (65.2%-67.0% reduction).

    “elinzanetant achieved a 65.2%-67.0% reduction in VMS frequency by Week 12 (OASIS 1/2)”

    Reviewin menopauseWeek 12

    Elinzanetant: Defining the Role of Dual Neurokinin-1 and Neurokinin-3 Receptor Antagonism for Management of Vasomotor Symptoms in Menopause

    Journal of menopausal medicine

  6. Elinzanetant decreases vasomotor symptoms in humans (moderate-to-severe vasomotor symptoms associated with menopause) (MD: -2.11, 95% CrI [-3.31, -0.92]).

    “Elinzanetant significantly reduced daily VMS frequency versus PRX (MD: -2.11 [-3.31, -0.92])”

    Reviewmoderate-to-severe vasomotor symptoms associated with menopause120 mgweek 12females

    Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis

    BJOG : an international journal of obstetrics and gynaecology

  7. Elinzanetant decreases vasomotor symptoms in humans (postmenopausal women with moderate-to-severe vasomotor symptoms) (MD = -2.75, 95% CI: [-3.83, -1.67]).

    “elinzanetant demonstrated a statistically significant difference in reducing both frequency and severity of VMSs at week 4 compared to placebo (MD = -2.75, 95% CI: [-3.83, -1.67], P < 0.00001”

    Reviewpostmenopausal women with moderate-to-severe vasomotor symptomsweek 4femalesn = 1,699

    Elinzanetant: Efficacy and safety in the management of vasomotor symptoms in postmenopausal women, a systematic review and meta-analysis with grading of recommendations assessment, development, and evaluation assessment

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

More on Vasomotor symptoms

Vasomotor symptoms

downin humans7

7 studies
  1. Elinzanetant decreases vasomotor symptoms in breast cancer receiving endocrine therapy.

    “elinzanetant demonstrated rapid and clinically meaningful reductions in moderate-to-severe VMS”

    Reviewin breast cancer receiving endocrine therapy

    Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant

    Breast (Edinburgh, Scotland)

  2. Elinzanetant decreases vasomotor symptoms in humans.

    “Fezolinetant, a selective NK 3 receptor antagonist, and elinzanetant, a dual NK1/NK3 receptor antagonist, provide rapid and clinically meaningful reductions in VMS”

    Review

    Neurokinin 3 Receptor Antagonists for Menopause Symptom Management

    Obstetrics and gynecology clinics of North America

  3. Elinzanetant decreases vasomotor symptoms in patients with absolute contraindications to MHT.

    “the approval of neurokinin-3 (NK3) receptor antagonists (fezolinetant and elinzanetant) represents a paradigm shift in mitigating VMS via direct hypothalamic modulation”

    Reviewin patients with absolute contraindications to MHT

    Precision Pharmacological Stratification and Targeted Management of Pathological Menopause: Evidence-Based Hormone Replacement Therapy Optimization, Non-Hormonal Pharmacotherapy, and Personalized Strategies in Premature Ovarian Insufficiency and Iatrogenic Forms

    International Journal of Drug Delivery Technology

  4. Elinzanetant decreases vasomotor symptoms in humans (menopause).

    “Clinical trials demonstrated statistically significant reductions in VMS frequency and severity compared with placebo.”

    Reviewmenopausefemales

    Elinzanetant: A Nonhormonal Treatment Option for Vasomotor Symptoms Associated With Menopause

    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

  5. Elinzanetant decreases vasomotor symptoms in humans (menopausal vasomotor symptoms).

    “demonstrate reduced frequency of vasomotor symptoms with their use”

    Reviewmenopausal vasomotor symptomsfemales

    Where do neurokinin receptor antagonists fit into management of menopausal vasomotor symptoms?

    JAAPA : official journal of the American Academy of Physician Assistants

  6. Elinzanetant decreases vasomotor symptoms in humans (P < .001).

    “All studies showed significant improvements in symptom frequency at week 12 compared to placebo (P < .001).”

    Reviewweek 12

    Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms

    The Annals of pharmacotherapy

  7. Elinzanetant decreases vasomotor symptoms in humans (moderate to severe VMS associated with menopause).

    “modulates the activity of hyperactive kisspeptin/neurokinin B/dynorphin neurones to reduce the frequency and severity of VMS”

    Reviewmoderate to severe VMS associated with menopause

    Elinzanetant: First Approval

    Drugs

Sleep disturbance

downin humans3

3 studies
  1. Elinzanetant decreases sleep disturbance in humans (PROMIS sleep disturbance T-score LS mean difference −4.9 (95% CI −6.0 to −3.9); ISI LS mean difference −3.0 (95% CI −3.7 to −2.2)).

    “Elinzanetant produced rapid-onset improvements in sleep disturbance that were sustained at week 12”

    ReviewPostmenopausal women experiencing ≥50 moderate-to-severe vasomotor symptoms/week; compared with placebo120 mg12 weeksfemales

    Elinzanetant for menopause-associated sleep disturbance: pooled analysis of two phase III studies

    Climacteric : the journal of the International Menopause Society

  2. Elinzanetant decreases sleep disturbance in humans.

    “Elinzanetant treatment improved sleep disturbance, assessed by the Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b total T-score”

    Reviewfemales

    Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program

    Maturitas

  3. Elinzanetant decreases sleep disturbance in humans (moderate to severe menopausal vasomotor symptoms).

    “Elinzanetant significantly reduced VMS frequency and severity and improved sleep disturbance”

    Reviewmoderate to severe menopausal vasomotor symptoms26 weeksfemales

    Searching for an oasis from the vasomotor symptoms of menopause: Could elinzanetant be the answer?

    Med (New York, N.Y.)

More on Sleep disturbance

Sleep disturbances

downin humans3

3 studies
  1. Elinzanetant decreases sleep disturbances in humans (moderate to severe menopausal vasomotor symptoms).

    “Elinzanetant also significantly improved sleep disturbances and menopause-related quality of life.”

    Reviewmoderate to severe menopausal vasomotor symptomsoralup to 52 weeksfemales

    Elinzanetant in moderate to severe menopausal vasomotor symptoms: a profile of its use

    Drugs & Therapy Perspectives

  2. Elinzanetant decreases sleep disturbances in humans.

    “Improvement in sleep disturbances and quality of life was also significant in OASIS 1, 2, and 4.”

    Review

    Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms

    The Annals of pharmacotherapy

  3. Elinzanetant decreases sleep disturbances in humans (menopause).

    “The dual antagonism of NK-1 and NK-3 receptors enhances its efficacy by alleviating menopause-related sleep disturbances and modulating peripheral vasodilatation.”

    Reviewmenopause

    A New Hope for Woman with Vasomotor Symptoms: Neurokinin B Antagonists

    Journal of clinical medicine

Menopausal vasomotor symptoms

downin humans2

2 studies
  1. Elinzanetant decreases menopausal vasomotor symptoms in humans (MHT contraindicated or not preferred).

    “non-hormonal drugs, such as paroxetine, fezolinetant and elinzanetant, offer effective alternative treatment options.”

    ReviewMHT contraindicated or not preferred

    Hormonal therapies are still first-line for menopausal vasomotor symptoms, but novel non-hormonal drugs are promising

    Drugs & Therapy Perspectives

  2. Elinzanetant decreases menopausal vasomotor symptoms in humans (moderate to severe menopausal vasomotor symptoms).

    “Elinzanetant significantly reduced VMS frequency and severity”

    Reviewmoderate to severe menopausal vasomotor symptoms26 weeksfemales

    Searching for an oasis from the vasomotor symptoms of menopause: Could elinzanetant be the answer?

    Med (New York, N.Y.)

More on Menopausal vasomotor symptoms

Vasomotor symptom frequency and severity

downin humans2

2 studies
  1. Elinzanetant decreases vasomotor symptom frequency and severity in humans (menopause; compared with placebo).

    “The studies demonstrated that both drugs significantly reduce the frequency and severity of vasomotor symptoms compared with placebo”

    Reviewmenopause; compared with placebofemales

    Neurokinin receptor antagonists in the treatment of menopausal vasomotor symptoms: Efficacy, safety, and impact on sleep and quality of life

    Research Society and Development

  2. Elinzanetant decreases vasomotor symptom frequency and severity in humans (postmenopause).

    “fezolinetant, a neurokinin-3 receptor antagonist and elinzanetant, a neurokinin-1-3 receptor antagonist, diminish the frequency and severity of vasomotor symptoms.”

    Reviewpostmenopausefemales

    Neurokinin Antagonists to Treat Vasomotor Symptoms-Possible Implications for Long-Term Health and Disease

    Journal of clinical medicine

Sleep

upin humans2

2 studies
  1. Elinzanetant improves sleep in humans (menopausal hot flashes).

    “Elinzanetant also improved their sleep and overall well-being.”

    Reviewmenopausal hot flashes

    Elinzanetant for the Treatment of Menopausal Hot Flashes: A Plain Language Review of the OASIS-1-4 Clinical Trial Results

    Women's health (London, England)

  2. Elinzanetant improves sleep in humans.

    “with elinzanetant offering additional improvements in sleep.”

    Review

    Neurokinin 3 Receptor Antagonists for Menopause Symptom Management

    Obstetrics and gynecology clinics of North America

Sleep disturbance

upin humans1downin humans1

2 studies
  1. Elinzanetant improves sleep disturbance in menopause.

    “produced clinically meaningful improvement in the PROMIS SD-SF 8b sleep disturbance score”

    Reviewin menopause

    Elinzanetant: Defining the Role of Dual Neurokinin-1 and Neurokinin-3 Receptor Antagonism for Management of Vasomotor Symptoms in Menopause

    Journal of menopausal medicine

  2. Elinzanetant decreases sleep disturbance in humans (moderate-to-severe vasomotor symptoms associated with menopause) (MD: -2.67, 95% CrI [-3.92, -1.42]).

    “Elinzanetant significantly improved sleep disturbance (PROMIS SD-SF-8b) score versus FEZO (MD: -2.67 [-3.92, -1.42]).”

    Reviewmoderate-to-severe vasomotor symptoms associated with menopause120 mgweek 12females

    Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis

    BJOG : an international journal of obstetrics and gynaecology

Wakefulness after sleep onset

no changein humans1downin humans1

1 study
  1. Elinzanetant showed no clear effect on wakefulness after sleep onset in humans (moderate-to-severe VMS and sleep disturbance) (LS-mean difference = -0.94 minutes, 90% CI: -13.96, 12.09).

    “Minimal group differences between treatment arms were estimated at Week 12 for PSG WASO (LS-mean difference = -0.94 minutes, 90% CI: -13.96, 12.09).”

    Human trialmoderate-to-severe VMS and sleep disturbance120 mg12 weeksfemalesn = 110

    Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study

    Sleep

  2. Elinzanetant decreases wakefulness after sleep onset in humans (moderate-to-severe VMS and sleep disturbance) (LS-mean difference = -22.50 minutes, 90% CI: -35.47, -9.52).

    “Elinzanetant was estimated to reduce PSG WASO at Week 4 versus placebo (least square [LS]-mean difference = -22.50 minutes, 90% CI: -35.47, -9.52).”

    Human trialmoderate-to-severe VMS and sleep disturbance120 mg4 weeksfemalesn = 110

    Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study

    Sleep

More on Wakefulness after sleep onset

Drug-induced liver injury

no changein humans1

1 study
  1. Elinzanetant showed no clear effect on drug-induced liver injury in humans.

    “Evaluation of eDISH hepatocellular and cholestatic plots did not identify any potential Hy’s law case in the pooled studies.”

    Human trial52 weeks

    Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant

    Drug safety

  2. Elinzanetant showed no clear effect on drug-induced liver injury in humans (pooled phase 1-3 clinical data) (0.12% vs 0.10% probably related cases).

    “The aggregated phase 1‒3 clinical data, supported by preclinical toxicology and individual case adjudications of participants with elevated liver enzymes, suggest that there is a low risk of liver toxicity for elinzanetant.”

    Human trialpooled phase 1-3 clinical data

    Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant

    Drug safety

More on Drug-induced liver injury

Alanine aminotransferase

no changein humans1

1 study
  1. Elinzanetant showed no clear effect on alanine aminotransferase in humans (0.5% vs 0.4%).

    “During weeks 1‒12 (the placebo-controlled period), ALT or AST elevations ≥ 3× ULN were reported in 4/755 (0.5%) participants treated with elinzanetant 120 mg and in 3/735 (0.4%) participants treated with placebo.”

    Human trial52 weeks

    Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant

    Drug safety

  2. Elinzanetant showed no clear effect on alanine aminotransferase in humans (pooled clinical program (phases 1-3)) (1.2% vs 1.0% ≥ 3× ULN).

    “In the clinical program (phases 1‒3), there was no imbalance between the elinzanetant and placebo groups in alanine aminotransferase (ALT) elevations up to 5×, 10×, or 20× the upper limit of normal (ULN).”

    Human trialpooled clinical program (phases 1-3)120 mgweeks 1-52

    Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant

    Drug safety

More on Alanine aminotransferase

Sleep continuity

upin humans1

1 study
  1. Elinzanetant improves sleep continuity in humans (moderate-to-severe VMS and sleep disturbance).

    “led to estimated improvements in sleep continuity over 12 weeks, supported by multimodal subjective and objective sleep outcomes.”

    Human trialmoderate-to-severe VMS and sleep disturbance120 mg12 weeksfemalesn = 110

    Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study

    Sleep

Lean mass index

upin humans1

1 study
  1. Elinzanetant increases lean mass index in humans (postmenopausal women).

    “Trending reductions in weight, BMI, and WC, along with increases in LMI and body water were observed with EZN vs PL.”

    Human trialpostmenopausal women52 weeks

    MON-745 The Impact Of Elinzanetant Treatment On Bone Health And Body Composition In Postmenopausal Women

    ENDO 2025 abstract

More on Lean mass index

Osteocalcin

downin humans1

1 study
  1. Elinzanetant decreases osteocalcin in humans (postmenopausal women).

    “Lower levels of circulating OC and P1NP were consistently observed over 52 wks of EZN treatment”

    Human trialpostmenopausal women52 weeks

    MON-745 The Impact Of Elinzanetant Treatment On Bone Health And Body Composition In Postmenopausal Women

    ENDO 2025 abstract

More on Osteocalcin

Bone mineral density loss

downin humans1

1 study
  1. Elinzanetant decreases bone mineral density loss in humans (postmenopausal women) (femoral neck 0.00% vs -1.22%, total hip -0.70% vs -1.37%, lumbar spine -0.57% vs -1.22%).

    “lower BMD reductions were seen in EZN vs PL at all skeletal sites”

    Human trialpostmenopausal women52 weeks

    MON-745 The Impact Of Elinzanetant Treatment On Bone Health And Body Composition In Postmenopausal Women

    ENDO 2025 abstract

All 28

What is elinzanetant linked with?

1

Studies link elinzanetant with treatment-emergent adverse events.

Treatment-emergent adverse events

upin humans1RR 1.12

1 study
  1. Elinzanetant raises the risk of treatment-emergent adverse events in humans (postmenopausal women with moderate-to-severe vasomotor symptoms) (RR = 1.12, 95% CI: [1.03, 1.22]).

    “elinzanetant was associated with a higher incidence of treatment-emergent adverse events (TEAEs) (RR = 1.12, 95% CI: [1.03, 1.22], P < 0.01)”

    Reviewpostmenopausal women with moderate-to-severe vasomotor symptomsfemalesn = 1,699

    Elinzanetant: Efficacy and safety in the management of vasomotor symptoms in postmenopausal women, a systematic review and meta-analysis with grading of recommendations assessment, development, and evaluation assessment

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Has elinzanetant been tested in people?

7 of 17 about aging

Yes: 6 trials in people have been published, and 16 trials are registered.

Approved

  • FDA Lynkuet

    Oct 24, 2025vasomotor symptoms due to menopause, moderate-to-severe vasomotor symptoms

  • EMA Lynkuet

    Nov 17, 2025Hot Flashes, Menopause, vasomotor symptoms, moderate-to-severe vasomotor symptoms

Repurposing

Who is developing elinzanetant?

1 company: Bayer.

Companies
  • BayerPhase 3vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer, hot flashes

Trial sponsors

  • Bayer

    Company16 trialsPhase 32,515 people

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 0Feb 2026: 2Mar 2026: 4Apr 2026: 2May 2026: 3Jun 2026: 0Jul 2026: 4Aug 2026: 0Sep 2026: 2Oct 2026: 8Nov 2026: 532 papers in 12 months
EClinicalMedicine

Elinzanetant’s safety profile appeared favorable in women

Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.

Meta-analysis · 1,519 peopleElinzanetant

See all 42 papers on elinzanetant